67Cu MeCOSar Octreotate (Clarity Pharmaceuticals)

N/A

Report date: 2026/01/04 20:00:05
NME

Base Information

Drug Name67Cu MeCOSar Octreotate (Clarity Pharmaceuticals)
Drug Alias Name67Cu MeCOSar Octreotate67-Cu-SARTATEcopper-67 labelled MeCOSar-Tyr3-octreotateSARTATE™ NETs Therapy(Clarity)
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[5] 
Mechanisms of ActionSomatostatin receptor 2 inducers
TargetsSomatostatin receptor 2
Therapy Area/IndicationsMeningiomaNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of MelbourneClarity Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesClarity Pharmaceuticals Ltd
Active IndicationsN/A
Inactive IndicationsMeningiomaNeuroblastoma

Other Information

ATC CodeN/A
Related LinksN/A